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Summary The purine analogue 2-chlorodeoxyadenosine (CdA) is unique compared with traditional antimetabolite drugs, as it has shown
equal activity in dividing and resting lymphocytes. Poly(ADP-ribose)polymerase (PARP) activation and consecutive NAD+ consumption have
been associated with the induction of apoptosis in resting cells. The potential of CdA to induce the p53-dependent DNA damage response
was assessed in resting and phytohaemagglutinine (PHA)-activated peripheral blood mononuclear cells (PBMCs) and compared with
cisplatin (DDP), a cell cycle-dependent and DNA-damaging agent that is mainly used in the treatment of solid tumours. Both drugs induced
transactivation of the p53 target genes wafl and mdm2, NAD+ consumption and apoptotic death. The expression pattern of p53 and waf1
suggests a partly p53-independent induction of waf1. The expression of c-myc and PARP, which both have a dual role in proliferation and
apoptosis, was selectively induced by CdA. Cell cycle stimulation increased the cytotoxic activity of both drugs. These data show that DDP is
also a potent inducer of apoptosis in resting and proliferating peripheral blood mononuclear cells. Activation of the p53-dependent DNA
damage response seems to be an important component of the toxic effect of CdA.
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Apoptosis is a genetically controlled physiological mechanism, by
which eukaryotic organisms remove their own unwanted cells. It
ensures homeostasis, as foreach newly formed cell anothercell has
to die to keep a perfect balance of cell numbers in the adult
organism. This suggests that the regulation of apoptosis and the
regulation ofproliferation are highly intertwined. The development
of cancer can be viewed as a derangement of this balance.
However, malignant transformation by various oncogenes renders
cancer cells more susceptible to apoptosis induction in an attempt
tocounterbalance proliferation (Fisher, 1994). This altered setpoint
of apoptosis induction in cancer cells is one reason for the benefi-
cial therapeutic ratio of chemotherapy. Despite a large variety of
specific drug-target interactions, most anti-cancer agents kill
cancer cells by inducing apoptosis (Hickman, 1992; Bomer et al,
1995). Recent evidence provides further support for a link between
proliferation and apoptosis, as the same genes are involved in the
regulation of the cell cycle and of chemotherapy-induced apo-
ptosis. Rapidly growing tumours seem to be more susceptible to
chemotherapy (Bomer, 1996; St Croix, 1996; Stone et al, 1996).
The induction of DNA damage is a central event for the action
ofmany anti-cancer agents. However, whether DNA damage leads
to apoptosis is critically dependent on the function of the p53
tumour-suppressor gene in the affected cell (Lowe et al, 1993;
Fisher, 1994). DNA damage increases the levels ofp53, which in
tum induces either growth arrest primarily at the G, phase of the
cell cycle or apoptosis, depending on the cellular context (Oren,
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1992; Vogelstein and Kinzler, 1992; Lane, 1993). The p53 protein
acts as a transcription factor and many ofits biological effects are
executed by transactivation of target genes, such as bax, waf] or
mdm2 (El-Deiry et al, 1993; Chen et al, 1994; Miyashita and Reed,
1995). However, p53-disabling mutations belong to the most
prevalent genetic aberrations in human cancer, and this fact might
contribute to the pleiotropic drug resistance ofmany tumours.
As most malignant tumours have both a low proliferative
capacity and a dysfunctional p53 tumour-suppressor gene, agents
with a proliferation and p53-independent mechanism of action
are very attractive for the treatment of cancer. The drug 2-
chlorodeoxyadenosine (CdA), a purine analogue with distinct
activity in lymphoproliferative disorders oflow-grade malignancy,
has been described to be equally active against dividing and
resting lymphocytes (Saven and Piro, 1994). CdA produces DNA
strand breaks in resting lymphocytes, probably by interfering with
the repair of spontaneously occurring DNA strand breaks. This
activates the DNA repair enzyme poly(ADP-ribose)polymerase
(PARP), which is dependent on NAD+ for the synthesis of
poly(ADP-ribose). It has been speculated that CdA stimulates
disproportionate NAD+ consumption by this mechanism, which
leads to apoptotic death (Seto et al, 1985, 1986). According to
these data, apoptosis by CdA is induced by NAD+ consumption
and should not be critically dependent on p53 function.
Because of this presumably unique activity of CdA compared
with traditional antimetabolite drugs (Saven and Piro, 1994), we
were interested in the mechanism, specificity and proliferation
dependence ofits effect. CdA was compared with cisplatin (DDP),
an alkylating metal complex compound with well-described intra-
cellular targets (Reed et al, 1996). In contrast to CdA, DDP
induces DNA strand breaks and apoptosis mainly in proliferating
cells (Evans and Dive, 1993; Demarcq et al, 1994). Human periph-
eral blood mononuclear cells (PBMCs) were chosen as the model
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system for our studies because of the lymphotropic activity of
CdA. The use of PBMCs enabled us to study the regulation of
apoptosis in untransformed human cells ex vivo. In addition, they
are a good example of resting Go phase cells and have been used
extensively as a model system for investigating the regulation of
cellular proliferation and entry into the cell cycle.
MATERIALS AND METHODS
Materials and PBMC culture
PBMCs were purified from whole blood of normal volunteer
donors by Ficoll-Hypaque sedimentation andcultured at 106 perml
in RPMI 1640 medium containing 10% heat-inactivated fetal
bovine serum. CdA was purchased from Lipomed Pharmaceuticals
(Basle, Switzerland), PHA from Seromed (Basle, Switzerland).
Cytotoxicity assays
Cytotoxicity was assessed using the Alamar Blue (Alamar,
Sacramento, CA, USA) oxidation-reduction indicator, which
changes fromblue (oxidized) to red (reduced) in response to meta-
bolic activity (Page et al, 1993). The dye was added at a final
concentration of 10% atthe indicated time points, incubated for 24
h and then measured using an excitation wavelength of 560 nm
and an emission wavelength of 590 nm with a CytoFluor II
platereader (PerSeptive Biosystems, Framingham, MA, USA).
Analysis of DNA integrity
DNA integrity was assessed as described (Borner et al, 1994). In
short, cell lysates were centrifuged at 27 000 g for 20 min. DNA
was extracted from the supernatant and treated with boiled bovine
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Figure 1 Effect of cytotoxic treatment on metabolic activity of resting and
stimulated PBMCs. DDP (10 gg ml-') or CdA (1 gg ml-') was added to
parallel samples of resting (DDP, CdA) and PHA (10gg ml-')-stimulated
(DDP+, CdA+) PBMCs. Fluorescence measurements were performed after
adding Alamar Blue dye for 24 h at the indicated time points of continuous
drug exposure. Effects of the respective treatment are indicated as relative
metabolic activity compared with untreated control, determined from
triplicates of a representative of three independent experiments. All samples
are from the same experiment
pancreatic RNAase A. Parallel samples were normalized
according to the initial cell number.
Northern blot analysis
Total RNA was extracted using theTRIzol RNA isolation kit (Gibco,
GrandIsland,NY,USA). Total RNA(10 ,ugpersample) was fraction-
ated on agarosegelscontaining 0.7% formaldehyde and transferred to
nylon membranes (Schleicher & Schuell). Hybridization with
random-primer 32P-labelled probes (1-2 x 106 c.p.m. ml-1 hybridiza-
tion solution) was performed for24 h at42°C. Filters were washed to
a final stringency of 0.1% standard saline citrate (SSC) at 650C.
Purified inserts were used as human cDNA probes: mdm2 [800 bp,
Hindm; generous gift from Dr B Vogelstein (Oliner et al, 1992)
through DrJGudas], wt-p53 (2.0kb, BamHI; purchased fromATCC,
Rockville, MD, USA), waf] [2.1 kb, BamHIIHindlI; generous gift
from Dr B Vogelstein (El-Deiry et al, 1993)] and c-myc (0.9kb,
ClaIIXbal). A988-bpprobeforPARPwas synthesizedbypolymerase
chain reaction (PCR) using cDNA from normal human lung as a
template. The primers were PARP-5' 5'-ATGGCGGAGTCTI-
CGGATAA-3' and PARP-3' 5'-GGTTGGGTGTCTGTGTCTIG-3'.
The reaction mixture was preincubated at 94°C (preheated block) for
3 min before performing 33 PCR cycles. Annealing was at 57°C,
elongation at74°C anddenaturation at94'C eachfor 1 min. The PCR
reaction mixture was prepared according to the instructions by the
manufacturer (Appligene/Oncor, Illkirch, France).
Western blot analysis
Cells were collected and lysed in 80 mm Tris pH 6.8, 2% sodium
dodecyl sulphate (SDS), 10% glycerol, 2% 2-0-mercaptoethanol
and 0.02% bromophenol blue at 100°C for 3 min. Proteins were
size fractionated on a 12% SDS-polyacrylamide gel andtransferred
to a Hybond nitrocellulose filter using a semi-dry electroblotting
apparatus. Membranes were probed using a mouse monoclonal
antibody against p53 (Ab-6, Oncogene Science) and visualized
using a secondary goat anti-mouse antibody conjugated with
horseradish peroxidase. Chemoiluminescence was performed with
enhanced chemiluminescence (ECL) (Amersham Life Science).
Flow cytometry
Attached cells were brought into suspension using 5 mM EDTA,
pelleted together with detached cells and washed in cold phos-
phate-buffered saline (PBS). The fresh samples were permeabi-
lized with Triton X-100 at low pH in the presence of serum
proteins (Darzynkiewicz et al, 1992). The metachromatic dye acri-
dine orange was used to identify simultaneouslyGO- and apoptotic
cells by measuring cellular DNA and RNA content. Intercalated
into double-strand DNA, acridine orange displays green fluores-
cence, dye-RNA interaction displays red fluorescence. As an
altemative method to stain apoptotic cells, DNA strand breaks
were labelled using the terminal deoxytransferase-mediated
deoxyuridine nick end-labelling assay (TUNEL) (Gavrieli et al,
1992; Gorczyca et al, 1993). After washing and fixation, cells
were processed using the ApopTag in situ apoptosis detection kit
according to the manufacturer's instructions (Appligene/Oncor).
Flow cytometry was performed on a FACScan flow cytometer
(Becton Dickinson, Mountain View, CA, USA), and cell popula-
tions were quantitated using Cell Quest software. Apoptosis was
morphologically confirmed by fluorescence microscopy.
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Figure 2 Agarose gel electrophoresis to detect DNA laddering. DNA from
PBMCs exposed to 1 9g ml-' CdA (C) or to 10 9g ml-' DDP (D) was
harvested at the indicated times after start of treatment
NAD measurement
NAD+ pools were measured using an enzymatic cycling assay
(Bernofsky and Swan, 1973). Each reaction tube contained 0.2 ml
ofeither cell extract or NAD+ standard, 0.1 ml ofalcohol dehydro-
genase (160 U ml-') and 1 ml of reaction mixture consisting of
600 mm ethanol, 0.5 mm MTT, 2 mm phenazine ethosulphate,
5 mm EDTA, 1 mg ofbovine serum albumin and 120 mM N-bis(2
hydroxyethyl)glycine, pH 7.8. The assay was initiated at 37°C in
the dark and was terminated after 20 min by adding 0.5 ml of
12 mm iodoacetate. The optical density of reduced MTT was
measured at 570 nm. All chemicals were purchased from Sigma
Chemicals, Buchs, Switzerland.
RESULTS
Cytotoxic activity in unstimulated and stimulated
PBMCs
PBMCs from individual healthy human blood donors were treated
with CdA or DDP over a period of72 h to assess the relative toxi-
city ofthese agents. To evaluate the impactofproliferative activity,
parallel samples were stimulated with 10gg ml-1 PHA while being
exposed to the respective chemotherapeutic drug. After a 24-h
treatment with PHA alone, 53% of the cells were in cell cycle
compartments other than Go as quantified by flow cytometry.
The cytotoxic activity ofCdA and DDP was assessed in several
ways. First, AlamarBlue was used, ametabolic assay thathas been
validated against other colorimetric viability stains (Page et al,
1993). Afterreduction in living cells, the AlamarBlue dye yields a
very strong fluorescent substrate. Figure 1 shows that CdA and
DDP led to a similar inhibition of resting PBMCs. Metabolic
activity of treated samples was 38% and 39% of baseline after a
72-h exposure to CdA and DDP respectively. Stimulation with
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Figure 3 Labelling of DNA breaks in apoptotic cells with biotinylated-dUTP (Biot-dUTP) by TUNEL. Fresh PBMCs were cultured and treated as described in
Figure 1. Apoptotic cells (Ap) are characterized by increased biot-dUTP content. Approximately 10 000 stained cells were examined by bivariate flow cytometric
analysis. A typical example of three independent experiments is shown
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Table 1 Quantification of chemotherapy-induced apoptosis by TUNEL
assay
Percentage of apoptotic cells (%)
Treatment 24 h 48 h 72 h
8 +1 - + - +
Control 9 15 12 31 13 35
CdA (1 gg ml-') 31 21 38 54 58 62
DDP (10 lg ml-') 24 24 47 64 49 50
- and + indicate whether incubation was without or with the addition of PHA
(10 ,ug ml-'). Fresh PBMCs were cultured as described in Figure 1. At the
indicated time points of cytotoxic treatment, cells were stained using the
TUNEL assay and quantified by flow cytometry. Approximately 10 000 cells
were examined for each analysis. A typical example ofthree independent
experiments is shown.
PHA led to an increased toxicity ofboth chemotherapeutic drugs,
but the difference was not significant.
DNA integrity oftreated and untreated PBMCs was analysed to
assess whether the drugs induced apoptosis. DNA from parallel
samples was extracted and separated on agarose gels. Figure 2
shows that treated cells displayed the intemucleosomal DNA frag-
mentation pattern characteristic ofapoptosis with increasing inten-
sity over time. However, CdA caused a more intensive DNA
laddering than DDP despite equal cytotoxicity in the Alamar Blue
assay. A possible explanation for this finding is that DDP led to an
increase of membrane permeability, resulting in the loss of small
DNA fragments as described for human prostate cancer cells
(Bomer et al, 1995). The TUNEL assay (Gavrieli et al, 1992;
Gorczyca et al, 1993) was used as an additional method for the
detection ofapoptotic cells (Figure 3). Labelled cells were quanti-
fied by FACS analysis (Table 1) and the results showed similar
apoptosis induction by CdA and DDP.
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Activation of p53, PARP, c-myc and the p53 target
genes wafl and mdm2
Both p53 and PARP are critically involved in the cellular response
to DNA damage and the induction of apoptosis (Lane, 1993;
Ashkenas and Werb, 1996). Another DNA damage inducible gene
is c-myc (Fornace et al, 1993), which also has a central role in
some forms ofapoptosis (Bissonette et al, 1992; Evan et al, 1992;
Shi et al, 1992). Unstimulated and PHA-activated PBMC from
individual donors were treated with CdA or DDP. DDP led only to
a faint p53 induction at 18 h and showed no effect on c-myc or
PARP mRNA levels (Figure 4 A and B). The function of p53 is
known to be mainly regulated at the post-transcriptional level
(Mosner et al, 1995). We assessed p53 protein induction by
Western blot. Figure 5 shows that both CdA and DDP led to a
gradually increasing p53 protein induction over 48 h.
Next, the induction ofthe p53 target genes wafi and mdm2 was
examined as a measure of the biological activity ofp53. CdA and
DDP induced wafl and mdm2 in a parallel fashion (Figure 4B),
which correlates well with the cytotoxic activity ofthe agents and
their induction ofp53 protein.
Figure 4 Northem blots showing (A) PARP and c-myc and (B) p53, waf1
and mdm2 mRNA induction by CdA or DDP treatment in resting and in
stimulated PBMCs. Fresh PBMCs were cultured and treated as described in
Figure 1. Total RNA was harvested atthe indicated times of treatment, and
equal amounts of RNA (10 ,ug) were electrophoresed on an
agarose-formaldehyde gel. The same filter was stripped several times and
hybridized with the probes indicated. Autoradiograms are shown and
ethidium bromide-stained gel with 28s and 18s rRNA demonstrating RNA
loading per lane is included in the bottom panel (A, bottom panel). These
results were confirmed in an independent experiment using PBMCs from a
different donor and an independent experiment with differenttime points of
RNA harvesting (6 and 24 h after drug exposure)
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Figure 5 Westem blot analysis of p53 protein. Fresh PBMCs were treated
with 10 ig ml-' DDP or 1 igg ml-' CdA for the indicated time periods. Protein
(100 ,ug) prepared from whole-cell extracts was analysed on each lane
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Table 2 Effects of CdA and DDP treatment on PBMC NAD+ pools
Control CdA (1 9g ml-') DDP (10,g ml-')
_.a +a + _ +
NAD+ content (%)
(relative to respective
untreated control) 100 100 41b 25c 75 7
NAD+ content (%)
(relative to untreated
control of resting PBMCs) 100 1700d 41d 430d 75 130
a and + indicate whether or not stimulated by addition of PHA (10 9g ml-')
b(NAD+ content of treated unstimulated sample/NAD+ content of unstimulated
control) x 100. c(NAD+ content of treated PHA-stimulated sample/NAD+
content of PHA-stimulated control) x 100. d(NAD+ content of respective
sample/NAD+ content of unstimulated control) x 100. Fresh PBMCs were
cultured as described in Figure 1. NAD+ was measured using an enzymatic
cycling assay (Bernofsky, 1973) at 72 h. A typical example of three
independent experiments is shown.
NAD+ consumption
PARP activation and NAD+ consumption have been described as
being important causes of apoptosis induction by CdA in resting
cells (Seto et al, 1985, 1986). Here, we considered the questions of
whether this mechanism of action is specific for CdA and ofhow
proliferation affects NAD+ consumption. CdA led to a more
pronounced drop of cellular NAD+ levels in quiescent PBMCs
than DDP. Stimulation by PHA led to a marked increase in cellular
NAD+ production (Table 2). However, this rise of consumable
NAD+ had no protective effect on PBMCs. There was no direct
correlation between NAD+ level and cytotoxic activity of the
drugs. CdA and DDP treatment of growth-stimulated cells led to
an even more complete NAD+ consumption compared with resting
cells. At the RNA level, only CdA induced PARP expression
(Figure 4A).
DISCUSSION
The precise biochemical changes by which CdA induces apoptosis
are speculative (Bryson and Sorkin, 1993; Saven and Piro, 1994).
In dividing cells, potential targets are DNA synthesis and the
ribonucleotide reductase (Griffig et al, 1989). It has been proposed
that the resulting deoxyribonucleoside triphosphate pool imbal-
ance provides the signal for an endonuclease, which leads to inter-
nucleosomal DNA degradation and apoptosis (Hirota et al, 1989).
In non-dividing cells, CdA has been shown to induce DNA strand
breaks, inhibition of RNA synthesis, a profound drop of NAD+,
ATP depletion and apoptotic cell death. As shown by Seto et al
(1985), adding nicotinamide, a precursor of NAD+, prevented
NAD+ depletion and partly protected PBMCs from the toxic effect
ofCdA, suggesting a causal role ofNAD+ depletion for apoptosis.
Our studies demonstrate that CdA and DDP are both strong
inducers of apoptosis in resting and proliferating PBMCs, despite
their presumably different biochemical mechanism ofaction. DDP
damages DNA by inducing crosslinks and intrastrand adduct
formation (Reed et al, 1996). Compared with other systems (Evans
and Dive, 1993; Demarcq et al, 1994), cell cycle activity does not
seem to be a requirement for the cytotoxic action of DDP in
PBMCs. Also, we show here that both CdA and DDP led to NAD+
consumption. However, this result does not suggest a causal role of
NAD+ consumption for apoptosis in this system, as the NAD+
content was higher in growth-stimulated apoptotic cells than in
unstimulated controls (Table 2). This contrasts with the findings of
Seto et al (1985), which showed that the prevention of NAD+
depletion by nicotinamide rendered resting PBMCs highly resis-
tant to CdA toxicity. However, others have found massive deple-
tion of NAD+ to be a late event in apoptosis, which is rather the
result ofthan the cause ofcell death (Sorenson et al, 1990; Yoon et
al, 1996). Only CdA led to a significant PARP mRNA induction,
despite the fact that NAD+ consumption was associated with both
CdA and DDP activity. This is in accordance with other data
showing PARP activity to be regulated dominantly at the post-
transcriptional level (Bhatia et al, 1990a). As CdA led to a slightly
stronger p53 response and apoptosis induction than DDP, it can be
speculated that other triggering events in addition to DNA damage
were present. CdA has been shown to lead to a depletion of ribo-
nucleotides (Griffig et al, 1989; Hirota et al, 1989) and this has
recently been described as being a DNA damage-independent
inductor ofp53 (Linke et al, 1996).
Many of the functions of p53 require transactivation of target
genes, such as wafi or mdm2. Mdm2 serves as an autoregulatory
feedback loop for p53 (Momand et al, 1992; Chen et al, 1994).
Waf1 is a cyclin-dependent kinase inhibitor and orchestrates GI
arrest to allow damage repairbefore the cell starts DNA replication
(El-Deiry et al, 1993; Harper et al, 1993). Determination of the
mechanism by which p53 induces apoptosis has been more elusive,
and the mechanism seems to be independent of wafl (Deng et al,
1995). We wereinterested intheeffectofCdA onp53 as, according
to the literature (Seto et al, 1985), energy depletion rather than
DNA damaging seems to be the prevailing mechanism of CdA
toxicity in non-dividing human lymphocytes. The pattem of wafl
induction by CdA and DDP suggests similar kinetics and quantity
of the DNA-damaging activity of the two drugs. Despite repeated
experiments, inconsistencies between p53 mRNA, p53 protein and
wafl induction remained. However, there have been observations
that higher doses of DNA-damaging agents can circumvent this
absolute requirement for p53, suggesting altemative p53-indepen-
dent pathways for wafl induction (Michieli et al, 1994).
PARP, c-myc and p53 have all been shown to play a dual role in
apoptosis and proliferation (Mercer and Baserga, 1985; Reed et al,
1986; Bhatia et al, 1990b; Evan et al, 1992), suggesting common
molecular pathways for these seemingly opposite cell fates. In
accordance with this dual role, these genes were similarly induced
by CdA treatment and mitogen stimulation in our experiments.
Whether c-myc expression is associated with apoptosis orprolifer-
ation depends upon the signaling context in a given cell. If acti-
vated in cells that are not naturally destined to undergo growth
stimulation, this conflicting signal can induce apoptosis (Evan
et al, 1992). Colombel et al (1992) have shown that castration-
induced apoptosis in quiescent epithelial prostate cells is associ-
ated with the exit from the Go state into a defective cell cycle
(Colombel et al, 1992). The fact that the cytotoxic action of DDP
did notrequire early p53, c-myc and PARP induction suggests that
this pathway is not an absolute requirement for apoptosis to
proceed in PBMCs.
Our data support the notion that CdA is a potent inducer of
apoptosis in non-dividing lymphoid cells, which gives a rationale
for the exceptional clinical activity of this drug against indolent
lymphoid malignancies. DDP is mostly used for the treatment of
solid tumours, in which it is the comerstone ofa variety ofcurative
treatment regimens. However, DDP has also been successfully
integrated into treatment regimens against aggressive lymphoid
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malignancies. The fact that both anti-cancer drugs were strong
inducers of apoptosis in resting and stimulated PBMCs might
reflect the low threshold for apoptosis induction of human
lymphoid cells (Fisher, 1994). Although previous research into the
activity of CdA and DDP has focused on different intracellular
targets, we have shown that both drugs activated p53 target genes
and led to significant NAD+ consumption. Also in view of its
limited non-haematological toxicity (Saven and Piro, 1994), CdA
could be a very attractive agent in the treatment of cancer.
However, the activity of CdA in solid tumours is limited by the
low ratio ofdeoxycytidine kinase to 5'-deoxynucleotidase in these
tissues, preventing intracellular activation ofCdA (Kawasaki et al,
1993). Manoeuvres to aid orcircumvent this activation step should
help to broaden the spectrum of this interesting drug to non-
lymphoid malignancies.
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